Table 1.

Baseline characteristics of participants randomized at week 0.

Characteristic	IDeg add‐on to liraglutide	Placebo add‐on to liraglutide
	(n = 174)	(n = 172)
Female/male, %	43.7/56.3	39.5/60.5
Race: white/black/Asian/other, %	80.5/12.6/5.2/1.7	87.8/6.4/2.3/3.5
Ethnicity: Hispanic or Latin American, %	9.8	11.0
Age, years	57.0 (±10.0)	57.3 (±9.4)
Weight, kg	90.7 (±18.2)	94.0 (±19.1)
BMI, kg/m2	32.0 (±5.7)	32.4 (±5.4)
Duration of diabetes, years	9.7 (±5.8)	9.3 (±5.4)
HbA1c, %	7.6 (±0.6)	7.6 (±0.6)
HbA1c*, mmol/mol	59.6	59.6
FPG
mmol/l	8.7 (±2.1)	9.1 (±2.2)
mg/dl	156.2 (±37.8)	164.0 (±39.5)

BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; IDeg, insulin degludec.

Data are mean ± standard deviation unless otherwise indicated.

^*Calculated values.